We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Yield10 Bioscience, Inc. (NASDAQ:YTEN) defied analyst predictions to release its first-quarter results, which were...
Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, announced today a change in the format of its Annual Meeting of Shareholders ("Annual Meeting") from an in-person to a virtual-only meeting, via webcast, due to the emerging public health impact of the coronavirus pandemic (COVID-19) and to support the health and well-being of the Company's shareholders, employees and their families. At the time Yield 10 Bioscience filed its definitive proxy materials on March 25, 2020, it had disclosed the possibility of hosting a virtual annual meeting in lieu of its customary in-person annual meeting as part of its precautions regarding the coronavirus or COVID-19. The annual meeting will be accessible to stockholders via the link: http://viewproxy.com/yield10bio/2020/vm.
Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, announced today that it achieved key milestones in an early development program in corn to evaluate novel seed yield traits. Corn is the highest value commercial crop grown in the United States. The Company’s corn program began in early 2019, centered around the successful deployment of novel traits discovered by Yield10 into corn by a major third-party agriculture company partner.
Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it will effect a 1-for-40 reverse stock split of its common stock, following stockholder approval of the reverse stock split at the Company's special stockholders meeting held on January 9, 2020. The 1-for-40 reverse stock split will be effective as of the close of business on Wednesday, January 15, 2020 and the Company's common stock will begin trading on a split-adjusted basis on Thursday, January 16, 2020. The reverse stock split will reduce the number of shares of the Company’s common stock currently outstanding from 39,986,201 shares to 999,655 shares.
Woburn-based agricultural company Yield10 Bioscience Inc. received shareholder approval to undergo a reverse stock split in order to avoid being delisted by the Nasdaq, the company revealed in a public filing Thursday.
Yield10 Bioscience, Inc. (Nasdaq:YTEN today announced that Sherri M. Brown, Ph.D. was appointed to the Company’s Board of Directors effective February 11, 2020. In connection with her appointment, Dr. Brown will serve as chair of a newly formed Science and Technology Committee of the Board. Dr. Brown previously served as a Special Commercial and Technical Advisor to the Company.
Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that it has submitted an "Am I Regulated?" letter to USDA-APHIS's Biotechnology Regulatory Services (BRS) to confirm that the use of CRISPR genome-edited trait C3007 in Camelina sativa plant lines for increased oil content does not meet the definition of a regulated article under 7 CFR Part 340 regulations. Once regulatory status of the plants is confirmed, Yield10 plans to conduct field tests of CRISPR genome-edited Camelina plants in the United States. “We have applied considerable effort and resources into the discovery and early development of a portfolio of novel traits with the potential to increase oil content in oilseed crops,” said Dr. Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience.
Woburn-based agricultural company Yield10 Bioscience Inc. is seeking stakeholders approval to effect a reverse stock split to address the risk of being delisted by the Nasdaq, the company revealed in a recent public filing.
Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, today announced the results from field tests conducted in the 2019 growing season in the United States and Canada. Data from the field tests suggest that novel traits can be successfully deployed in the oil biosynthesis pathway using CRISPR genome-editing technology to boost seed oil content in Camelina. Additional results recorded in the field studies suggest that the activity and expression of trait C3004 can boost photosynthetic efficiency in Camelina, an outcome that supports further field work in 2020.
Companies In The News Are: AVID, GPX, YTEN, SFIX
Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited C3007 trait in Camelina sativa plant lines designed to increase oil content. Yield10’s submission along with the USDA-APHIS BRS response is posted on the USDA’s website. In January 2020, Yield10 submitted an “Am I Regulated?” letter to the BRS, requesting confirmation of the regulatory status for Camelina plant lines containing the Company’s novel, CRISPR genome-edited C3007 trait.
Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today that it has received a letter from The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement. The letter noted that as of January 30, 2020, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the Company has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and Nasdaq considers the matter closed.
NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Yield10 Bioscience, Inc. (NASDAQ:YTEN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 19, 2020 at ...
WOBURN, Mass., March 12, 2020 -- Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its fourth quarter.
WOBURN, Mass., March 19, 2020 -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and twelve months.
Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, today announced that the Company has secured all of the regulatory permits required to conduct field tests for multiple traits at sites in the United States and Canada contracted for the 2020 growing season. Yield10’s 2020 Field Test Program will evaluate several novel traits in Camelina and canola. Yield10 utilizes the oilseed plant Camelina sativa to rapidly evaluate the activity of novel performance traits for development in Camelina as well as for licensing in key commercial crops, including canola, soybean, corn and other crops.
Yield10 Bioscience, Inc. (YTEN), an agricultural bioscience company, announced today that the Company will report its first quarter 2020 financial results and provide a corporate update on Thursday, May 14, 2020. Management will host a conference call on Thursday, May 14, 2020 at 6:00 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. International callers should call +1-201-689-8354.
WOBURN, Mass., May 14, 2020 -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three months ended March 31,.